{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:56:30Z","timestamp":1778504190479,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T00:00:00Z","timestamp":1457308800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Funding was provided by Ardea Biosciences\/AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40261-016-0386-y","type":"journal-article","created":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T05:24:54Z","timestamp":1457328294000},"page":"443-452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters"],"prefix":"10.1007","volume":"36","author":[{"given":"Zancong","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Tain","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Wallach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanqun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gillen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,7]]},"reference":[{"key":"386_CR1","doi-asserted-by":"crossref","unstructured":"Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology (Oxford). 2009:48(Suppl 2):ii9\u2013ii14.","DOI":"10.1093\/rheumatology\/kep087"},{"issue":"10","key":"386_CR2","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"Suppl 2","key":"386_CR3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/annrheumdis-2014-eular.4117","volume":"73","author":"P Richette","year":"2014","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Coyfish M, et al. Updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2014;73(Suppl 2):783 (Abstract SAT0531).","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"386_CR4","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312\u201324.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 3","key":"386_CR5","first-page":"320","volume":"68","author":"L Yeh","year":"2009","unstructured":"Yeh L, Shen Z, Kerr B, Tamai I, Hingorari V, Ong V, et al. RDEA594: a potent URAT1 inhibitor without affecting other important renal transporters, OAT1 and OAT3. Ann Rheum Dis. 2009;68(Suppl 3):320 (Abstract THU0452).","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"386_CR6","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/rheumatology\/ket487","volume":"53","author":"R Fleischmann","year":"2014","unstructured":"Fleischmann R, Kerr B, Yeh LT, Suster M, Shen Z, Polvent E, et al. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology (Oxford). 2014;53(12):2167\u201374.","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"386_CR7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2133\/dmpk.24.37","volume":"24","author":"H Kusuhara","year":"2009","unstructured":"Kusuhara H, Sugiyama Y. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet. 2009;24(1):37\u201352.","journal-title":"Drug Metab Pharmacokinet."},{"issue":"3","key":"386_CR8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","volume":"158","author":"A Kalliokoski","year":"2009","unstructured":"Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693\u2013705.","journal-title":"Br J Pharmacol."},{"key":"386_CR9","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Drug interaction studies\u2014study design, data analysis, implications for dosing, and labeling recommendations. Draft guidance. FDA Web site. Available from: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm292362.pdf . Accessed 14 Sept 2015."},{"issue":"3","key":"386_CR10","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s11095-007-9401-6","volume":"25","author":"M Sato","year":"2008","unstructured":"Sato M, Iwanaga T, Mamada H, Ogihara T, Yabuuchi H, Maeda T, et al. Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res. 2008;25(3):639\u201346.","journal-title":"Pharm Res."},{"issue":"4","key":"386_CR11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1124\/dmd.114.060673","volume":"43","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Warren MS, Zhang X, Diamond S, Williams B, Punwani N, et al. Impact on creatinine renal clearance by the interplay of multiple renal transporters: a case study with INCB039110. Drug Metab Dispos. 2015;43(4):485\u20139.","journal-title":"Drug Metab Dispos."},{"issue":"8","key":"386_CR12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/0091270006289848","volume":"46","author":"R Khosravan","year":"2006","unstructured":"Khosravan R, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. J Clin Pharmacol. 2006;46(8):855\u201366.","journal-title":"J Clin Pharmacol."},{"issue":"8","key":"386_CR13","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.30389","volume":"63","author":"RA Terkeltaub","year":"2011","unstructured":"Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4\/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63(8):2226\u201337.","journal-title":"Arthritis Rheum."},{"issue":"2","key":"386_CR14","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/ki.2014.66","volume":"86","author":"EI Lepist","year":"2014","unstructured":"Lepist EI, Zhang X, Hao J, Huang J, Kosaka A, Birkus G, et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int. 2014;86(2):350\u20137.","journal-title":"Kidney Int."},{"issue":"2\u20133","key":"386_CR15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.mam.2012.11.004","volume":"34","author":"H Motohashi","year":"2013","unstructured":"Motohashi H, Inui K. Multidrug and toxin extrusion family SLC47: physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K. Mol Aspects Med. 2013;34(2\u20133):661\u20138.","journal-title":"Mol Aspects Med."},{"issue":"2","key":"386_CR16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.clpt.6100038","volume":"81","author":"YY Lau","year":"2007","unstructured":"Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007;81(2):194\u2013204.","journal-title":"Clin Pharmacol Ther."},{"key":"386_CR17","unstructured":"LIPITOR [prescribing information]. New York, NY: Pfizer Inc., 2009. Available at: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=587 ."},{"issue":"8","key":"386_CR18","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1124\/dmd.106.012930","volume":"35","author":"J Noe","year":"2007","unstructured":"Noe J, Portmann R, Brun ME, Funk C. Substrate-dependent drug\u2013drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007;35(8):1308\u201314.","journal-title":"Drug Metab Dispos."},{"issue":"11","key":"386_CR19","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1124\/dmd.113.053025","volume":"41","author":"MJ Zamek-Gliszczynski","year":"2013","unstructured":"Zamek-Gliszczynski MJ, Bao JQ, Day JS, Higgins JW. Metformin sinusoidal efflux from the liver is consistent with negligible biliary excretion and absence of enterohepatic cycling. Drug Metab Dispos. 2013;41(11):1967\u201371.","journal-title":"Drug Metab Dispos."},{"issue":"5","key":"386_CR20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s002280050303","volume":"52","author":"M Bindschedler","year":"1997","unstructured":"Bindschedler M, Degen P, Flesch G, de GM, Preiswerk G. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur J Clin Pharmacol. 1997;52(5):371\u20138.","journal-title":"Eur J Clin Pharmacol."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-016-0386-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0386-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T19:15:09Z","timestamp":1553627709000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-016-0386-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,7]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["386"],"URL":"https:\/\/doi.org\/10.1007\/s40261-016-0386-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,7]]}}}